Page last updated: 2024-12-07

win 57273

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Win 57273: bactericidal for Legionella pneumophila [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121960
CHEMBL ID315498
SCHEMBL ID7866482
MeSH IDM0173074

Synonyms (15)

Synonym
CHEMBL315498
1-cyclopropyl-7-(2,6-dimethyl-4-pyridyl)-6-fluoro-4-oxo-quinoline-3-carboxylic acid
1-cyclopropyl-7-(2,6-dimethyl-4-pyridinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid
win 57273
1-cyclopropyl-7-(2,6-dimethylpyridin-4-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
3-quinolinecarboxylic acid, 1-cyclopropyl-7-(2,6-dimethyl-4-pyridinyl)-6-fluoro-1,4-dihydro-4-oxo-
123942-04-1
win-57273
SCHEMBL7866482
FNKLCGHPPNAPBJ-UHFFFAOYSA-N
1-cyclopropyl-7-(2,6-dimethyl-4-pyridinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
DTXSID60154154
1-cyclopropyl-7-(2,6-dimethylpyridin-4-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
PD163160
1-cyclopropyl-7-(2,6-dimethylpyridin-4-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylicacid

Research Excerpts

Overview

WIN 57273 is a new fluoroquinolone with excellent in vitro activity versus gram-positive pathogens. It has an expanded spectrum of activity against Staphylococcus spp.

ExcerptReferenceRelevance
"WIN 57273 is a new fluoroquinolone with excellent in vitro activity versus gram-positive pathogens, including methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis and gentamicin-susceptible and -resistant Enterococcus faecalis. "( WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.
Kaatz, GW; Seo, SM, 1990
)
3.16
"WIN 57273 is a new fluoroquinolone that has an expanded spectrum of activity against Staphylococcus spp. "( In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.
Barry, AL; Jones, RN, 1990
)
2.03

Dosage Studied

ExcerptRelevanceReference
" leprae; temafloxacin and sparfloxacin were the most active, being fully bactericidal at all three dosage schedules."( Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.
Gelber, RH; Iranmanesh, A; Murray, L; Siu, P; Tsang, M, 1992
)
0.28
" tuberculosis H37Rv strain, the minimal effective dosage of sparfloxacin, as assessed by survival rate, spleen enlargement and gross lung lesions, was 12."( In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.
Grosset, J; Ji, B; Truffot-Pernot, C, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID41277Minimum Inhibitory concentration measured against Bacteroides fragilis ATCC 252851995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID69668Minimum Inhibitory concentration measured against Escherichia coli ATCC 1-259221995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID209257Minimum Inhibitory concentration measured against Streptococcus faecalis ATCC 292121995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID209776Minimum Inhibitory concentration measured against Streptococcus pyogenes ATCC 63011995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID163281Minimum Inhibitory concentration measured against Pseudomonas aeruginosa ATCC 278531995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID206021Minimum Inhibitory concentration measured against Staphylococcus aureus ATCC 292131995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.55)18.7374
1990's21 (95.45)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.80 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]